{
Catalent, Inc.

Companies

}
novo nordisk faces stock plunge after disappointing results for obesity drug
Novo Nordisk's shares plummeted over 21% following disappointing results from the Phase 3 trial of its obesity drug CagriSema, which achieved a 22.7% average weight reduction, falling short of the expected 25%. Analysts have reacted with downgrades, citing safety concerns and underperformance compared to competitors. Despite achieving primary study objectives, the market's response reflects significant investor disappointment.
aktiencheck.de
Danish Krone Catalent, Inc. Novo Nordisk A/S Eli Lilly and Company DNK Florent Cespedes Emmanuel Papadakis Jo Walton Peter Welford Show more
Healthcare, Market Report
15:35 20.12.2024
merck shifts focus to biotech and obesity as keytruda exclusivity looms
Merck & Co. is shifting its focus from TIGIT and LAG-3 inhibitors to a subcutaneous version of Keytruda and a PD-1x/VEGF bispecific, while entering the obesity market with a preclinical GLP-1 receptor agonist from Hansoh Pharma for $112 million. Sanofi reported promising mid-stage results for its TL1A antibody duvakitug in inflammatory bowel disease, achieving significant remission rates, while Vertex Pharmaceuticals faced setbacks with its NaV1.8 inhibitor suzetrigine in chronic pain trials. Novo Nordisk completed a $16.5 billion acquisition of Catalent to address supply issues for semaglutide, despite ongoing shortages, while Novartis announced the closure of two MorphoSys sites, affecting 330 employees, following an $800 million write-down on pelabresib.
firstwordpharma.com
United States Dollar Sanofi Vertex Pharmaceuticals Inc Merck & Co., Inc. Catalent, Inc. Novartis AG Novo Nordisk A/S USA Show more
Healthcare, Market Report
04:47 20.12.2024
global cmo in healthcare market analysis and future growth prospects
The global CMO in Healthcare market report provides a comprehensive analysis of market structure, growth factors, and competitive landscape, forecasting trends from 2024 to 2030. Key players include Accellent, Boehringer Ingelheim, and Catalent, with a focus on regional dynamics across North America, Europe, and Asia. The report highlights market segmentation by type and application, emphasizing the driving forces and potential restraints impacting future developments.
rock-news.at
Catalent, Inc. Boehringer Ingelheim KG Neil Thomas Show more
Healthcare, Market Report
10:03 22.11.2024
blow fill seal packaging services in healthcare market trends and growth forecast
The Blow-Fill-Seal (BFS) Packaging Services in Healthcare market is experiencing significant growth, driven by rising demand and technological advancements. A comprehensive report analyzes market trends, competitive dynamics, and future prospects, highlighting key players like Recipharm AB and Nephron Pharmaceuticals. The study also delves into consumption patterns, pricing strategies, and market segmentation, providing valuable insights for stakeholders.
openPR.com
Catalent, Inc. Nephron Pharmaceuticals Corporation Corporation Robert Bosch Packaging Technology GmbH Vertiv Holdings Co Recipharm AB Alice Mutum Unither Mr. Shah Robert Bosch Horizon Pharmaceuticals Inc. Show more
Healthcare, Market Report
11:23 12.11.2024
citi hires jeff stute to enhance healthcare mergers and acquisitions team
Jeff Stute, a seasoned investment banker with three decades of experience, is joining Citigroup as vice president of North American healthcare mergers, effective December. His recruitment aims to enhance Citi's healthcare M&A capabilities amid a competitive landscape, following recent promotions within the team. Stute previously held significant roles at Perella Weinberg Partners and JPMorgan Chase, advising on major pharmaceutical deals.
Zonebourse
United States Dollar Perella Weinberg Partners The Goldman Sachs Group, Inc. JPMorgan Chase & Co. Catalent, Inc. Citizens, Inc. USA Nishant Jadav Jeff Stute Kevin Cox Sumit Khedekar Torrey Browder Show more
Finance & Economy, Market Report
15:14 04.11.2024
Citi hires Jeff Stute to enhance healthcare mergers and acquisitions team
Citi has recruited Jeff Stute from Perella Weinberg Partners to enhance its healthcare M&A division, where he will serve as vice president starting in December. With over 30 years of experience, Stute aims to strengthen Citi's market position amid a competitive landscape, following recent promotions within the team. The healthcare M&A market has seen a 13% decline in deal volume this year, highlighting the challenges ahead.
Boursorama
United States Dollar Perella Weinberg Partners The Goldman Sachs Group, Inc. Citigroup Inc. JPMorgan Chase & Co. Centerview Partners Novo Nordisk A/S Catalent, Inc. USA Novo Nordisk Jeff Stute Sabrina Valle Kevin Cox Torrey Browder Show more
Finance & Economy, News Article
15:10 04.11.2024
Citigroup promotes three bankers to enhance healthcare investment banking efforts
Citigroup has promoted Sumit Khedekar to global head of healthcare, alongside Nishant Jadav as Global Head of Healthcare Services and Michael Guarino as head of healthcare services in North America. These appointments reflect the bank's strategy to enhance its investment banking presence in the healthcare sector, following notable transactions like the $16.5 billion sale of Catalent to Novo Nordisk.
Boursorama
United States Dollar Catalent, Inc. Novo Nordisk A/S Bank of America Corporation Citigroup Inc. Credit Suisse Anlagestiftung The Goldman Sachs Group, Inc. USA Sumit Khedekar Nishant Jadav Michael Guarino Show more
Finance & Economy, News Article
18:43 22.10.2024
global cdmo market projected to reach 279 billion by 2026
The global contract development and manufacturing organization (CDMO) market, valued at USD 130.8 billion in 2018, is projected to reach USD 278.98 billion by 2026, growing at a CAGR of 10.0%. This growth is driven by rising demand for novel therapies, increasing complexity of treatments, and strategic partnerships between pharmaceutical companies and CDMOs. Key trends include market consolidation and significant investments in infrastructure, while challenges such as stringent regulations may hinder growth.
fortunebusinessinsights.com
United States Dollar Recipharm AB Baxter International Inc. Catalent, Inc. Thermo Fisher Scientific Inc. CHE USA Paragon Bio Services Cambrex Corporation Avista Pharma Solutions Inc Catalent Recipharm AB Show more
Healthcare, Market Report
09:00 14.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Central Bank Actions Banking Regulations Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Mergers & Acquisitions Cryptocurrency & Blockchain Regulations Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Emerging Startups Cryptocurrency Regulations Inflation Rates & CPI Data SEC & Financial Compliance Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK NGA FIN COL AUT VGB LIE TUR
Companies:
Credit Suisse Real Estate Fund Siat BlackRock, Inc. Coinbase Global, Inc. Solana USD Ethereum USD Apple Inc. Ripples USD Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Thomas Jordan Gary Gensler Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.